miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung

View original at globenewswire.com
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung BioNTech treibt Onkologiestrategie mit dem Fokus auf zwei tumorübergreifende (Pan-Tumor)-Programme sowie Kombinationsansätze weiter voran, um das gesamte Spektrum von Krebserkrankungen vom frühen bis zum späten S…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trastuzumab Pamirtecan BLA filing planned for 2026 pending FDA feedback

    80% confidence

  • 2025 SG&A costs expected to be €550-650M, reduced from previous guidance of €650-750M

    80% confidence

  • Pumitamig showed encouraging anti-tumor activity, positive PFS trend, controlled safety profile, and low discontinuation rate in ES-SCLC Phase 2 trial

    80% confidence

  • ROSETTA Breast-01 Phase 3 trial for TNBC will start by end of 2025

    80% confidence

  • Autogene Cevumeran showed strong durable immune responses up to 1.5 years post-treatment with broad immune response correlated with extended PFS

    80% confidence

  • 2025 CapEx expected to be €200-250M, reduced from previous guidance of €250-350M

    80% confidence

  • BioNTech expects no positive net income for FY 2025

    80% confidence

  • BNT111 demonstrated deep durable antitumor responses with statistically significant improvement in ORR vs historical control

    80% confidence

  • 2025 revenue guidance is €2,600-2,800M

    80% confidence

  • 2025 R&D costs expected to be €2,000-2,200M, reduced from previous guidance of €2,600-2,800M

    80% confidence

Data points we hold from this source

BioNTech SE · outstanding shares240455450 shares
BioNTech SE · r and d costs564.8 million_EUR
BioNTech SE · sg and a costs148.5 million_EUR
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
BioNTech veröffentlicht Ergebnisse für das dritte Quartal 2025 sowie Informationen zur Geschäftsentwicklung — Source | Via News | es.VIA.NEWS